Arcellx announced that the FDA has cleared the company’s Investigational New Drug (IND) application for ACLX-001, an engineered cell therapy for the treatment of multiple myeloma. ACLX-001 is the first clinical application of the company’s ARC-SparX platform of controllable and adaptable cell therapies.
6445212 T8CEPLWI items 1 apa default asc 1
email@example.com. (2021, April 6). Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma. Arcellx. https://arcellx.com/arcellx-announces-fda-clearance-of-ind-application-for-aclx-001-a-controllable-cell-therapy-utilizing-the-companys-arc-sparx-platform-for-the-treatment-of-multiple-myeloma/ Cite
In syngeneic mouse colorectal cancer (CRC) models and human patient-derived CRC organoid models, atractylenolide I treatment promoted the cytotoxicity of CD8+ T cells and thus profoundly enhanced the efficacy of immune checkpoint blockade therapy.
[Journal of Clinical Investigation]
6445218 RYVHHW6C items 1 apa default asc 1
Xu, H., Jeught, K. V. der, Zhou, Z., Zhang, L., Yu, T., Sun, Y., Li, Y., Wan, C., So, K., Liu, D., Frieden, M., Fang, Y., Mosley, A. L., He, X., Zhang, X., Sandusky, G. E., Liu, Y., Meroueh, S. O., Zhang, C., … Lu, X. (2021). Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. The Journal of Clinical Investigation. https://doi.org/10.1172/JCI146832 Cite
Researchers describe a detailed protocol for the purification and ex vivo expansion of primary, nonmalignant human germinal center B cells.
Scientsts showed that HIV could penetrate the epithelial surface to interact with sub-epithelial resident mononuclear phagocytes in anogenital explants and defined the full array of subsets that were present in the human anogenital and colorectal tissues that HIV may encounter during sexual transmission.
6445218 9W4LPPCJ items 1 apa default asc 1
Rhodes, J. W., Botting, R. A., Bertram, K. M., Vine, E. E., Rana, H., Baharlou, H., Vegh, P., O’Neil, T. R., Ashhurst, A. S., Fletcher, J., Parnell, G. P., Graham, J. D., Nasr, N., Lim, J. J. K., Barnouti, L., Haertsch, P., Gosselink, M. P., Di Re, A., Reza, F., … Harman, A. N. (2021). Human anogenital monocyte-derived dendritic cells and langerin+cDC2 are major HIV target cells. Nature Communications, 12(1), 2147. https://doi.org/10.1038/s41467-021-22375-x Cite
Researchers combined single-cell RNA-sequencing and antigen receptor lineage analysis to characterize a large number of triple-negative breast cancer infiltrated immune cells and report a comprehensive atlas of tumor-infiltrated B-lymphocytes.
6445218 CYAHIWQE items 1 apa default asc 1
Hu, Q., Hong, Y., Qi, P., Lu, G., Mai, X., Xu, S., He, X., Guo, Y., Gao, L., Jing, Z., Wang, J., Cai, T., & Zhang, Y. (2021). Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. Nature Communications, 12(1), 2186. https://doi.org/10.1038/s41467-021-22300-2 Cite
The authors investigated the expression and function of Eotaxin-1 (CCL11) in rheumatoid arthritis fibroblast-like synoviocytes.
Researchers concluded that, after pre-term birth onset, a shift from immunoregulation towards inflammation takes place in cord blood cells that were reportedly representative of the fetal compartment.
[Journal of Reproductive Immunology]
6445212 CHBSZTVV items 1 apa default asc 1
City of Hope and CytoImmune Therapeutics Inc. have entered into worldwide exclusive license agreements to several patent applications related to methods to generate large numbers of fully functional natural killer (NK) cells derived from umbilical cord blood and compositions of chimeric receptors (CAR) for targeting NK cells to tumors.
[CytoImmune Therapeutics, Inc. (BusinessWire, Inc)]
6445218 nan items 1 apa default asc 1
Researchers used PET tracers to measure the access to and uptake of glucose and glutamine by specific cell subsets in the tumor microenvironment. Notably, myeloid cells had the greatest capacity to take up intratumoral glucose, followed by T cells and cancer cells, across a range of cancer models.
6445218 TLLSLCDD items 1 apa default asc 1
Reinfeld, B. I., Madden, M. Z., Wolf, M. M., Chytil, A., Bader, J. E., Patterson, A. R., Sugiura, A., Cohen, A. S., Ali, A., Do, B. T., Muir, A., Lewis, C. A., Hongo, R. A., Young, K. L., Brown, R. E., Todd, V. M., Huffstater, T., Abraham, A., O’Neil, R. T., … Rathmell, W. K. (2021). Cell-programmed nutrient partitioning in the tumour microenvironment. Nature, 1–7. https://doi.org/10.1038/s41586-021-03442-1 Cite
CD4+ T cells in patients with IPEX syndrome and Foxp3-deficient mice were analyzed by single-cell cytometry and RNA-sequencing, revealing heterogeneous Treg-like cells, some very similar to normal Treg cells, others more distant.
6445218 FIF6VSVG items 1 apa default asc 1
Zemmour, D., Charbonnier, L.-M., Leon, J., Six, E., Keles, S., Delville, M., Benamar, M., Baris, S., Zuber, J., Chen, K., Neven, B., Garcia-Lloret, M. I., Ruemmele, F. M., Brugnara, C., Cerf-Bensussan, N., Rieux-Laucat, F., Cavazzana, M., André, I., Chatila, T. A., … Benoist, C. (2021). Single-cell analysis of FOXP3 deficiencies in humans and mice unmasks intrinsic and extrinsic CD4 + T cell perturbations. Nature Immunology, 1–13. https://doi.org/10.1038/s41590-021-00910-8 Cite
Using an original ex vivo model of B-cell receptor-induced proliferation of chronic lymphocytic leukemia cells, researchers generated 108 temporal transcriptional and proteomic profiles from one hour up to four days after BCR activation.
6445218 VJGEDC65 items 1 apa default asc 1
Schleiss, C., Carapito, R., Fornecker, L.-M., Muller, L., Paul, N., Tahar, O., Pichot, A., Tavian, M., Nicolae, A., Miguet, L., Mauvieux, L., Herbrecht, R., Cianferani, S., Freund, J.-N., Carapito, C., Maumy-Bertrand, M., Bahram, S., Bertrand, F., & Vallat, L. (2021). Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic lymphocytic leukemia. Leukemia, 1–12. https://doi.org/10.1038/s41375-021-01221-5 Cite